Cited by 25Nonmelanoma Skin Cancer StudiesPhotodynamic Therapy Research StudiesSkin Protection and Aging

Topical Methyl Aminolevulinate

Siddiqui, M Asif A, Perry, Caroline M, Scott, Lesley J·2004·American Journal of Clinical Dermatology

Abstract

Methyl aminolevulinate (MAL), an ester of aminolevulinic acid, has been used effectively as a topical photosensitizing agent in the photodynamic therapy (PDT) of epidermal lesions such as actinic keratosis (AK) and basal cell carcinoma (BCC). The optimal regimen for MAL-PDT (as used in all clinical trials) is MAL 160 mg/g applied for 3 hours before illumination with red light (570-670 nm) at a total light dose of 75 J/cm(2), as determined in dose-finding trials. In randomized, multicenter, phase III clinical trials, treatment with MAL-PDT resulted in a complete response (i.e. complete disappearance) in up to 91% of AK lesions and up to 97% of BCC lesions. With regard to lesion response rates, MAL-PDT was superior to placebo-PDT (in AK or BCC), and at least as effective as cryotherapy (in AK or BCC) or excision surgery (in BCC). Cosmetic outcome with MAL-PDT was excellent to good in the vast majority of patients, and was judged by investigators to be better than with cryotherapy (in AK or BCC) or surgery (in BCC). black triangle Over 75% of BCC lesions treated with MAL-PDT, including difficult-to-treat BCC, were still in remission 12-24 months after the last treatment. MAL-PDT was generally well tolerated in clinical trials. The most frequently reported adverse events were local phototoxicity reactions, most of which were of mild to moderate intensity, resolved rapidly and were rarely treatment limiting.

Integrity signals

Registry

Crossref · 10.2165/00128071-200405020-00006

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • FDA approved PDT with 160 mg/g MAL cream (Metvixia) applied 3 h before red light illumination for thin and moderately thick AK lesions in 2004.

    “Based on these clinical trials, in 2004, the FDA approved PDT with 160 mg/g MAL cream (Metvixia) applied 3 h before red light (centered at ~630 nm) illumination for both thin and moderately thick AK lesions.”
  • PDT with 160 mg/g MAL and red light showed up to 91% and 97% complete responses in AK and BCC lesions, respectively, in randomized multicenter phase III clinical trials.

    “PDT with this MAL protocol and red light illumination (with deeper tissue penetration than blue light) showed up to 91% and 97% complete responses in AK and BCC lesions, respectively, in randomized multicenter phase III clinical trials [21].”
  • MAL-PDT is at least equally effective as cryotherapy or excision surgery for AK and BCC, with better cosmetic outcome.

    “This response rate renders MAL-PDT at least equally effective as cryotherapy or excision surgery, two conventional therapies for AK and BCC. The cosmetic outcome with MAL-PDT is better than with the latter two.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Siddiqui, M. A. A., Perry, C. M., & Scott, L. J.
Corresponding author
Siddiqui, M Asif A
Venue
American Journal of Clinical Dermatology
Published
2004
Volume
5
Issue
2
Pages
127-137
ISSN
1175-0561 (ISSN-L)
OpenAlex
W1978239236
Cited by
24
References
41
Citations by year
2025: 1 · 2023: 1 · 2022: 1 · 2018: 1 · 2017: 1 · 2014: 1
FWCI
1.58
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Clinical Dermatology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
methyl aminolevulinate, photodynamic therapy, actinic keratosis, basal cell carcinoma, topical photosensitizer, red light irradiation, treatment response, cosmetic outcome, long-term remission, phototoxicity
MeSH terms
Administration, Cutaneous, Aminolevulinic Acid, Basal Cell Carcinoma, Humans, Keratosis, Photochemotherapy, Skin Neoplasms, Photosensitizing Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review